Metagenomi, which is developing MGX-001, a gene-editing therapy for hemophilia A, is preparing to initiate investigational new drug (IND)-enabling activities that seek to support the therapy’s transition from preclinical to clinical testing. The move is backed by preclinical studies in nonhuman primates that show the treatment led to…

After a decade of living alongside my husband, Jared, and his severe hemophilia B, I’ve learned that not all bleeding is as straightforward as it may seem. Bleeds vary widely, not just in size but in severity and impact. What might look minor can be excruciating, while larger bleeds,…

I can still feel the sting of frustration as I replay that night at the recent National Conference for Women and Teens with hemophilia in Detroit. The conference was a place of empowerment — a chance to connect, learn, and share experiences with others who live with hemophilia…

Centessa Pharmaceuticals is discontinuing the clinical development of SerpinPC, its experimental under-the-skin therapy for people with hemophilia A and hemophilia B with or without inhibitors. The therapy was being evaluated in several Phase 2 clinical trials. The decision follows the recent approval of Pfizer’s Hympavzi…

When people hear about epilepsy, they often picture sudden, dramatic falls, frantic efforts to keep the person safe, and looming threats of injury. For my husband, Jared, these are indeed valid concerns. “What if he falls?” “What if he bumps his head?” These questions cross people’s minds — and…